 This provides a unique opportunity for the development of AR-specific peptides.Even though small molecule antagonists and NTD antagonist targeting AF2 surface differ in binding sites, they both inhibit AR function by disrupting AF2 function.Therefore, mechanistically, these NTD antagonists may also be classified as ‘AF2 antagonists’.